Plasma Cell Myeloma Clinical Trials

98 clinical trials for Plasma Cell Myeloma across international registries, including 9 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab — RECRUITING · PHASE2
• Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial — RECRUITING · PHASE3
• Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma — RECRUITING · PHASE1
• Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment — RECRUITING · PHASE3
• Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma — RECRUITING · NA
• Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization — RECRUITING · PHASE1
• Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies — RECRUITING
• Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma — RECRUITING · NA
• Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma — RECRUITING · PHASE2
• Cardiovascular Reserve Evaluation in Survivors of Transplant, CREST Study — ACTIVE_NOT_RECRUITING
• Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant — ACTIVE_NOT_RECRUITING · PHASE2
• Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma — ACTIVE_NOT_RECRUITING · PHASE2
• A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) — COMPLETED
• Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer — SUSPENDED · PHASE1
• Lenalidomide Maintenance in Plasma Cell Myeloma — ACTIVE_NOT_RECRUITING · PHASE2
• Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant — ACTIVE_NOT_RECRUITING · PHASE1
• SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy — ACTIVE_NOT_RECRUITING · PHASE1
• Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma — COMPLETED · PHASE2
• A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant — ACTIVE_NOT_RECRUITING · PHASE3
• Decision Aid Website in Helping to Make Decisions About Fertility in Participants With Cancer — ACTIVE_NOT_RECRUITING · NA
• Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study — ACTIVE_NOT_RECRUITING · PHASE1
• Elotuzumab and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma — ACTIVE_NOT_RECRUITING · PHASE2
• Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant — ACTIVE_NOT_RECRUITING · PHASE1
• Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study — COMPLETED · NA
• SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Stopping Maintenance Therapy in People With Multiple Myeloma in MRD-Negative Remission — ACTIVE_NOT_RECRUITING
• Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients — COMPLETED · PHASE3
• Evaluation of Comprehensive Geriatric Assessment and Laboratory Biomarkers in Elderly Patients With Multiple Myeloma — COMPLETED
• Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant — COMPLETED · PHASE2
• Alternating Ixazomib Citrate and Lenalidomide as Maintenance Therapy After Stem Cell Transplant in Treating Patients With Multiple Myeloma — COMPLETED · PHASE2
• Stem Cell Transplant With or Without Tbo-filgrastim in Treating Patients With Multiple Myeloma or Non-Hodgkin Lymphoma — COMPLETED · PHASE2
• Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma — ACTIVE_NOT_RECRUITING · PHASE3
• Home Based Daratumumab Administration for Patients With Multiple Myeloma — COMPLETED · PHASE4
• Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies — COMPLETED · PHASE2
• A Phase 3 randomized, open-label, multicenter study of isatuximab (SAR650984) in combination with lenalidomide and dexamethasone versus lenalidomide and dexamethasone in patients with high-risk smoldering multiple myeloma — TERMINATED · PHASE3
• First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma — COMPLETED · PHASE1
• Evaluating Effectiveness of Powered Drill Bone Marrow Biopsy — COMPLETED · NA
• Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma — ACTIVE_NOT_RECRUITING · PHASE3
• Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma — TERMINATED · PHASE2
• Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis — COMPLETED · PHASE1
• Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer — TERMINATED · PHASE2
• Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL — TERMINATED · PHASE1
• Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple Myeloma — COMPLETED · PHASE2
• Telehealth Exercise Intervention to Improve Physical Function and Frailty in Multiple Myeloma Survivors — COMPLETED · NA
• Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma — TERMINATED · PHASE1
• Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma — COMPLETED · PHASE2
• Understanding the Risk of Blood Clots and Bleeding in Patients With Hematological Malignancies, HAT Study — COMPLETED
• Melphalan Hydrochloride in Treating Participants With Newly-Diagnosed Multiple Myeloma Undergoing Donor Stem Cell Transplantation — COMPLETED · PHASE1
• Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With High-Risk Multiple Myeloma — ACTIVE_NOT_RECRUITING · PHASE2
• Exercise Prescription for the Improvement of Quality of Life in Elderly Patients With Multiple Myeloma — COMPLETED · NA

Refine this search